Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

It is certainly possible that today’s bottlenecks will prove to be rather short-lived as companies increasingly learn to ...

StarkWare made its name building infrastructure to scale Ethereum. Its technology powers Starknet, a network that speeds up ...

As the Oregon National Guard lawsuit proceeds, it’s become clear that right-wing content creators have a direct line to the ...

B y any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

There has been – to use the parlance of the kids – a vibe shift in the AI industry. All the way up from scrappy AI startups ...

Dave Gray has put together a pretty solid free Python video tutorial that clocks in at around 9 hours. It came out in 2023, ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...